To build a predictive model, we evaluated the HER2DX assay in pre-treated tumours from 116 patients with early-stage HER2-positive breast cancer treated with neoadjuvant trastuzumab-based chemotherapy (Figure. Here, ERBB2 is linked to neoplasm.